The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2023

Filed:

Aug. 14, 2020
Applicant:

Ngm Biopharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Daniel David Kaplan, San Mateo, CA (US);

Xuecai Ge, Menlo Park, CA (US);

Hui Tian, Foster City, CA (US);

Assignee:

NGM Biopharmaceuticals, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/16 (2006.01); C07K 16/26 (2006.01); C07K 16/18 (2006.01); A61K 39/05 (2006.01); A61K 38/04 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/26 (2013.01); A61K 39/05 (2013.01); C07K 16/18 (2013.01); A61K 38/04 (2013.01); A61K 2039/505 (2013.01);
Abstract

The present disclosure provides binding agents that modulate the interaction between liver-expressed antimicrobial peptide 2 (LEAP2) and growth hormone secretagogue receptor (GHSR). Specifically, the present disclosure provides binding agents, such as LEAP2 peptides that bind GHSR and methods of their use to treat or ameliorate a neuroendocrine and/or metabolic disease or disorder such as obesity, diabetes, acromegaly, gigantism and/or Prader-Willi syndrome. The present disclosure also provides binding agents, such as antibodies, that bind LEAP2, and methods of their use to, e.g., treat or ameliorate a neuroendocrine and/or metabolic disease or disorder such as cachexia, anorexia, or other wasting syndromes, increase growth hormone levels, or increase GHSR activity.


Find Patent Forward Citations

Loading…